苏洛培南或环丙沙星治疗女性非复杂性尿路感染:一项3期随机试验
本研究将非复杂性尿路感染女性随机分配至苏洛培南组(5天)或环丙沙星组(3天)。在环丙沙星不敏感病原体患者中,苏洛培南优效于环丙沙星(62.6% vs 36.0%);在敏感病原体患者中,苏洛培南未达非劣效(66.8% vs 78.6%);合并分析中苏洛培南非劣效于环丙沙星(65.6% vs 67.9%)。
要点
- 环丙沙星不敏感uUTI患者中,苏洛培南优效于环丙沙星。
- 环丙沙星敏感uUTI患者中,苏洛培南未达非劣效。
- 苏洛培南组腹泻发生率高于环丙沙星组(12.4% vs 2.5%)。
核心结论
- 苏洛培南在非复杂性尿路感染治疗中非劣效于环丙沙星。
- 在环丙沙星不敏感病原体所致非复杂性尿路感染患者中,苏洛培南优效于环丙沙星。
- 在环丙沙星敏感病原体患者中,苏洛培南未达非劣效,主要由接受环丙沙星者无症状性菌尿发生率较低所驱动。
研究设计与样本
- 3期随机试验,将非复杂性尿路感染女性患者随机分配至苏洛培南5天组或环丙沙星3天组。
- 主要终点为第12天临床和微生物学应答的总体成功。
- 对环丙沙星不敏感病原体患者比较苏洛培南的优效性;对环丙沙星敏感病原体患者比较非劣效性;采用预设分层统计检验,若任一亚组达到优效或非劣效,则在合并人群中检验主要终点。
主要发现
- 环丙沙星不敏感人群中,苏洛培南总体成功率为62.6%,环丙沙星为36.0%(差值26.6%;95%CI 15.1至7.4;P<.001)。
- 环丙沙星敏感人群中,苏洛培南总体成功率为66.8%,环丙沙星为78.6%(差值-11.8%;95%CI -18.0至5.6),苏洛培南未达非劣效。
- 合并分析中,苏洛培南总体成功率为65.6%,环丙沙星为67.9%(差值-2.3%;95%CI -7.9至3.3),苏洛培南非劣效于环丙沙星。
- 腹泻在苏洛培南组发生率高于环丙沙星组(12.4% vs 2.5%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited treatment options for uncomplicated urinary tract infection (uUTI) caused by resistant pathogens. Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic active against multidrug-resistant pathogens that cause uUTIs. METHODS: Patients with uUTI were randomized to 5 days of sulopenem or 3 days of ciprofloxacin. The primary endpoint was overall success, defined as both clinical and microbiologic response at day 12. In patients with ciprofloxacin-nonsusceptible baseline pathogens, sulopenem was compared for superiority over ciprofloxacin; in patients with ciprofloxacin-susceptible pathogens, the agents were compared for noninferiority. Using prespecified hierarchical statistical testing, the primary endpoint was tested in the combined population if either superiority or noninferiority was declared in the nonsusceptible or susceptible population, respectively. RESULTS: In the nonsusceptible population, sulopenem was superior to ciprofloxacin, 62.6% vs 36.0% (difference, 26.6%; 95% confidence interval [CI], 15.1 to 7.4; P <.001). In the susceptible population, sulopenem was not noninferior to ciprofloxacin, 66.8% vs 78.6% (difference, -11.8%; 95% CI, -18.0 to 5.6). The difference was driven by a higher rate of asymptomatic bacteriuria (ASB) post-treatment in patients on sulopenem. In the combined analysis, sulopenem was noninferior to ciprofloxacin, 65.6% vs 67.9% (difference, -2.3%; 95% CI, -7.9 to 3.3). Diarrhea occurred more frequently with sulopenem (12.4% vs 2.5%). CONCLUSIONS: Sulopenem was noninferior to ciprofloxacin in the treatment of uUTIs. Sulopenem was superior to ciprofloxacin in patients with uUTIs due to ciprofloxacin-nonsusceptible pathogens. Sulopenem was not noninferior in patients with ciprofloxacin-susceptible pathogens, driven largely by a lower rate of ASB in those who received ciprofloxacin. CLINICAL TRIAL REGISTRATION: NCT03354598.
引用
- Dunne MW, Aronin SI, Das AF, et al. Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial. Clin Infect Dis. 2023. PMID: 36069202. doi:10.1093/cid/ciac738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。